Related Experiment Video
Updated: Jun 28, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach
Jessica Petiti1, Ymera Pignochino2,3, Aurora Schiavon2
1Division of Advanced Materials Metrology and Life Sciences, Istituto Nazionale di Ricerca Metrologica (INRiM), 10135 Turin, Italy.
Abstract:
Acute myeloid leukemia (AML) is a complex hematologic malignancy with high morbidity and mortality. Nucleophosmin 1 (NPM1) mutations occur in approximately 30% of AML cases, and NPM1-mutated AML is classified as a distinct entity. NPM1-mutated AML patients without additional genetic abnormalities have a favorable prognosis. Despite this, 30-50% of them experience relapse. This study aimed to investigate the potential of total RNAseq in improving the characterization of NPM1-mutated AML patients. We explored genetic variations independently of myeloid stratification, revealing a complex molecular scenario. We showed that total RNAseq enables the uncovering of different genetic alterations and clonal subtypes, allowing for a comprehensive evaluation of the real expression of exome transcripts in leukemic clones and the identification of aberrant fusion transcripts. This characterization may enhance understanding and guide improved treatment strategies for NPM1mut AML patients, contributing to better outcomes. Our findings underscore the complexity of NPM1-mutated AML, supporting the incorporation of advanced technologies for precise risk stratification and personalized therapeutic strategies. The study provides a foundation for future investigations into the clinical implications of identified genetic variations and highlights the importance of evolving diagnostic approaches in leukemia management.
Insights
Total RNA sequencing reveals complex genetic alterations in Nucleophosmin 1 (NPM1)-mutated Acute Myeloid Leukemia (AML). This advanced characterization identifies diverse clonal subtypes and aberrant transcripts, improving risk stratification for better patient outcomes.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a serious blood cancer with high mortality rates.
- Nucleophosmin 1 (NPM1) mutations are found in about 30% of AML cases, defining a specific subtype.
- While NPM1-mutated AML without other genetic issues has a good prognosis, 30-50% of patients still relapse.
Purpose of the Study:
- To explore how total RNA sequencing can improve the characterization of NPM1-mutated AML patients.
- To investigate genetic variations and clonal subtypes beyond standard myeloid stratification.
- To identify aberrant fusion transcripts and evaluate exome transcript expression in leukemic cells.
Main Methods:
- Utilized total RNA sequencing (RNAseq) to analyze genetic variations in NPM1-mutated AML.
- Explored molecular profiles independently of traditional myeloid stratification methods.
- Identified genetic alterations, clonal subtypes, and fusion transcripts.
Main Results:
- Total RNAseq revealed a complex molecular landscape in NPM1-mutated AML.
- The study uncovered distinct genetic alterations and clonal subtypes.
- Aberrant fusion transcripts were identified, providing a comprehensive view of exome transcript expression.
Conclusions:
- Total RNAseq offers enhanced characterization of NPM1-mutated AML, revealing molecular complexity.
- This approach aids in identifying diverse genetic alterations and clonal subtypes.
- Findings support using advanced technologies for precise risk stratification and personalized treatment strategies in AML management.
More Related Videos
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
12:44Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis
Published on: November 11, 2014
